Gilead's Acquisition of Arcellx and Biogen's Purchase of Apellis Ease Restructuring Pressures on Biotech
Increased M&A Activity and Easing of Restructuring Pressures
The biopharmaceutical industry's job market in Q2 2026 shows a noticeable easing of the layoff trend that began last year. A total of 17 companies announced layoffs, a significant decrease from the 33 companies in Q1 and 64 companies in the same period last year. This is attributed to the stabilization of the macroeconomic environment, increased M&A activity, and improved access to capital through IPOs. However, the survival gap based on clinical trial success is expected to widen.
Large-Scale M&A Deals Facilitate Funding and Restructure Employment
Large-scale M&A transactions are resolving the financial difficulties of biotech companies while simultaneously leading to the reduction of redundant personnel. Gilead (GILD) completed the acquisition of Arcellx (ACLX) for $7.8 billion to secure anito-cel, a BCMA-targeted CAR-T cell therapy for multiple myeloma. Biogen (BIIB) also acquired Apellis (APLS) for $5.6 billion to gain access to Syfovre, a treatment for geographic atrophy. These deals provide survival opportunities for the acquired companies but also involve unavoidable layoffs, such as the reduction of 108 employees in Gilead's Kite division and personnel adjustments in Biogen's early research division at Apellis.
Employment Impact from Clinical Failures and Regulatory Hurdles
Clinical trial results and regulatory decisions by regulatory bodies can lead to immediate and large-scale layoffs, threatening the survival of companies. Replimune (REPL), which was developing RP1, a melanoma treatment, laid off 124 employees after receiving a Complete Response Letter (CRL) from the FDA. Passage Bio (PASG), which faced regulatory challenges with its PBFT02 gene therapy for Alzheimer's disease, also reduced its workforce by 75%. Passage Bio ultimately opted for a reverse merger with Remix Therapeutics to explore an exit strategy.
Bankruptcy Protection and Sale of Platform Assets
Companies facing financial constraints are seeking to survive by quickly selling assets under bankruptcy protection (Chapter 11 Bankruptcy). Sangamo (SGMO) filed for bankruptcy and laid off 51 employees, representing 40% of its workforce, and agreed to sell its prion disease program, ST-506, to Lilly (LLY) for $50 million. It also entered into a stalking horse agreement with Astellas (ALPMY) to sell ST-920, a treatment for Fabry disease, for a $25 million upfront payment and $25 million in milestone payments, becoming a pathway for large pharmaceutical companies to absorb platform assets at a low cost.
Polarization in the Biotech Sector and Differentiated Employment Recovery
Despite the overall stabilization of the job market, there is a clear difference between large pharmaceutical companies and early-stage biotech companies. Takeda (TAK) is undergoing a restructuring involving 4,500 layoffs as part of a JPY 140 billion restructuring plan, and BioNTech (BNTX) is reducing its manufacturing workforce by 1,860. NewLimit's $435 million mega-round investment is increasing employment in late-stage companies, while early-stage companies that have not received venture capital funding are facing continued pressure to reduce costs and lay off employees, leading to a significant polarization.
The trend of stabilizing employment in the biotech sector reflects the improved access to capital and the widening gap between companies. In the short term, the acquisition of Arcellx, a late-stage asset with anito-cel (Phase 2) for multiple myeloma, by Gilead for $7.8 billion will concentrate funds on companies with late-stage assets, which will accelerate the restructuring of the $30 billion market currently dominated by J&J's 'Carvykti'. In the medium to long term, the acquisition of Sangamo's Fabry disease gene therapy ST-920 (Phase 1/2) by Astellas for $50 million, a company facing financial difficulties, will lead to increased M&A activity of promising platforms, further intensifying the technological dominance of large pharmaceutical companies. Regulatory hurdles, such as the FDA's CRL for Replimune's melanoma candidate RP1 (Phase 2/3), will force researchers to adopt more aggressive restructuring measures or strategic exit strategies like a reverse merger with Remix Therapeutics. Ultimately, the ability of early-stage companies to manage their burn rate in a high-cost environment and the direction of R&D resource allocation by large pharmaceutical companies will determine their long-term investment attractiveness.